NeuroNews
(Return to Newsletter Index)
FDA Approves New Tool for Treatment of Chronic Migraine
By Shabbir A. Abbasi, M.D., M.R.C.P. (U.K.), Division of Neurology/Movement Disorders
Migraine is a painful and often debilitating form of headache. The Food and Drug Administration (FDA) recently approved the use of Botox injections as a treatment to prevent chronic migraine. In this case “chronic migraine” sufferers are defined as patients with severe migraines lasting 4 hours or more for more than 15 days each month.
There are large numbers of people with intractable and frequent migraines, and these individuals may be good candidates for Botox treatment. The treatment involves multiple injections in the frontalis, temporalis, and other muscles in the head.
For chronic migraine patients, newly approved Botox treatment may serve to reduce the frequency of painful headaches and improve a patient’s quality of life.
Dr. Shabbir A. Abbasi, a NENA specialist in Movement Disorders and Parkinson’s Disease, has extensive experience in the use of Botox for a variety of clinical applications.
|
